| 000 | 01869 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517031321.0 | ||
| 264 | 0 | _c20160421 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdv214 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFerreri, A J M | |
| 245 | 0 | 0 |
_aHigh-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cAug 2015 |
||
| 300 |
_a1760-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aClarithromycin _xadministration & dosage |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aEye Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell, Marginal Zone _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMouth Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasms, Multiple Primary _xdrug therapy |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aStomach Neoplasms _xdrug therapy |
| 700 | 1 | _aSassone, M | |
| 700 | 1 | _aKiesewetter, B | |
| 700 | 1 | _aGovi, S | |
| 700 | 1 | _aScarfò, L | |
| 700 | 1 | _aDonadoni, G | |
| 700 | 1 | _aRaderer, M | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 26 _gno. 8 _gp. 1760-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdv214 _zAvailable from publisher's website |
| 999 |
_c24863339 _d24863339 |
||